A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery

20081,136 citationsJournal Articlebronze Open Access

Authors

Dean Fergusson · University of Ottawa

Paul C. Hébert · University of Ottawa

C. David Mazer · University of Toronto

Stephen E. Fremes · University of Toronto

Charles MacAdams · Libin Cardiovascular Institute of Alberta

John M. Murkin · Western University

Kevin Teoh ·

Abstract

Despite the possibility of a modest reduction in the risk of massive bleeding, the strong and consistent negative mortality trend associated with aprotinin, as compared with the lysine analogues, precludes its use in high-risk cardiac surgery. (Current Controlled Trials number, ISRCTN15166455 [controlled-trials.com].).

Topics & Keywords

Blood transfusion and management Hyperglycemia and glycemic control in critically ill and hospitalized patients Trauma, Hemostasis, Coagulopathy, Resuscitation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 358, Issue 22, pp. 2319-2331

DOI: 10.1056/nejmoa0802395

Field-Weighted Citation Impact: 48.27